Seeking Alpha
18 Aug 2026, 15:45 UTC · 2h ago
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
18 Aug 2026, 15:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo and neurological improvement over standard of care. — Positive Phase 3 results are the primary driver of valuation for biotech assets as they indicate a high probability of regulatory success.
+0.80Monopar expects to complete the rolling NDA for ALXN1840 in the coming months. — The transition from trial to filing is a major near-term catalyst that reduces timeline uncertainty for commercialization.
+0.60FDA approval of ALXN1840 could result in a Priority Review Voucher (PRV). — PRVs have significant independent market value as they can be sold to other companies or used to accelerate another drug's approval.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is rated as a Strong Buy with a positive outlook on its radiotherapeutic development and the upcoming FDA catalyst for ALXN1840.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
6h ago
